ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Human Requirements for the Nutrient Choline

This study is currently recruiting participants.
Verified by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), April 2008

Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00065546
  Purpose

The purpose of this study is to increase our understanding of how much choline humans need to get from their diet. Choline is an essential nutrient found in many foods, including eggs and milk. In addition to dietary sources, choline can be made in the liver. Choline is important in making membranes or wrappers for all the cells in the body and for making chemicals that allow nerve cells to work properly. In a previous study we found that the dietary requirement for choline varies greatly from person to person. This was caused, in part, by how much estrogen a person has and their genetic makeup. We are conducting this study to explore how estrogen levels and specific differences in genes influence choline requirements so that we can refine the dietary recommendations for this nutrient.


Condition Intervention
Healthy
Other: Estrogen plus choline depletion diet
Other: Placebo plus choline depletion diet
Other: Pre-menopausal women with SNPs given a low choline diet

MedlinePlus related topics:   Menopause   

ChemIDplus related topics:   Choline    Choline bitartrate    Choline chloride    Choline dihydrogen citrate    Choline salicylate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Other, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment
Official Title:   Human Requirements for the Nutrient Choline

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:
  • Evidence of liver or muscle dysfunction (based on elevations in CPK, AST, ALT), or increased liver fat (measured by liver MRI) [ Time Frame: Labs measured every 3-4 days throughout 62-day trial. Liver MRI performed on study days 1, 10, 31, 52, 62. ] [ Designated as safety issue: No ]

Estimated Enrollment:   60
Study Start Date:   June 2007
Estimated Study Completion Date:   November 2011
Estimated Primary Completion Date:   November 2011 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Active Comparator
Post-menopausal women randomized to receive estrogen replacement therapy.
Other: Estrogen plus choline depletion diet
Post-menopausal subjects receive estrogen and are then challenged with a low choline diet to determine if estrogen protects them from induction of choline deficiency.
2: Placebo Comparator
Post-menopausal women randomized to receive a placebo.
Other: Placebo plus choline depletion diet
Post-menopausal women are randomized to receive a placebo and are then subjected to a low choline diet to determine if clinical signs of choline deficiency can be induced.
3: Experimental
Pre-menopausal women with specific genetic variants.
Other: Pre-menopausal women with SNPs given a low choline diet
Pre-menopausal women with specific genetic polymorphisms in genes related to choline metabolism are placed on a choline depletion diet to determine if the SNPs increase or decrease the risk of diet-induced choline deficiency.

Detailed Description:

Choline is an essential nutrient essential used for the structural integrity and signaling functions of cell membranes, cholinergic neurotransmission, and lipid transport/metabolism. Choline is obtained from the diet and from endogenous biosynthesis catalyzed by the enzyme phosphatidylethanolamine N-methyltransferase (PEMT). The major premise for this proposal is that humans require a dietary source of choline and that this requirement has significant individual variation and is modulated by estrogen and common genetic polymorphisms. The promoter of the PEMT gene is estrogen responsive, and we hypothesize that estrogen status influences the dietary requirement for choline. We identified other common single nucleotide polymorphisms (SNPs) that increase or decrease the likelihood that a human will develop organ dysfunction when fed a low choline diet. Experiments are proposed that will refine our understanding of estrogen-mediated induction of the PEMT promoter; determine whether postmenopausal women treated with estrogen have a decreased susceptibility to developing organ dysfunction associated with choline deficiency; determine the prevalence of SNPs that increase susceptibility to choline deficiency in the population and examine dietary choline requirements in humans with these SNPs.

  Eligibility
Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Healthy
  • Non-smoker
  • BMI between 18 and 34
  • Normal mammogram in last 12 months (post-menopausal women only)

Exclusion Criteria:

  • Hormone or estrogen therapy
  • Allergic to soy, eggs, wheat
  • History of breast, uterine, or other estrogen-dependent cancer
  • Liver or kidney problems
  • History of circulation, bleeding, or blood-clotting disorder
  • Anemia or evidence of iron overload
  • Hyperthyroidism, neurological disorder, or autoimmune disease
  • Diabetes controlled by insulin
  • Positive serology for HIV or Hepatitis B or C
  • Alcohol or illegal drug misuse/abuse
  • Pacemaker, aneurysm clip, cardiac heart valve, mechanical devices/implants
  • Other metal in body (i.e. injured by a BB, shrapnel, or metallic object)
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00065546

Locations
United States, North Carolina
University of North Carolina     Recruiting
      Chapel Hill, North Carolina, United States, 27599
      Contact: Brigitte Stephenson, MPH, RD     919-408-3320 ext 32     bjstep@unc.edu    
      Contact: Leslie M Fischer, PhD, MPH, RD     919 408-3320 ext 31     lfischer@email.unc.edu    
      Principal Investigator: Steven H Zeisel, MD, PhD            

Sponsors and Collaborators

Investigators
Principal Investigator:     Steven H Zeisel, MD, PhD     The University of North Carolina, Chapel Hill    
Study Director:     Leslie M Fischer, PhD, MPH, RD     The University of North Carolina, Chapel Hill    
  More Information


Responsible Party:   University of North Carolina at Chapel Hill ( Steven H. Zeisel, MD, PhD - Professor of Nutrition and Pediatrics, Director, UNC Clinical Nutrition Research Center )
Study ID Numbers:   HRNUT (DK55865)
First Received:   July 28, 2003
Last Updated:   April 22, 2008
ClinicalTrials.gov Identifier:   NCT00065546
Health Authority:   United States: Federal Government

Study placed in the following topic categories:
Choline
Healthy

Additional relevant MeSH terms:
Antimetabolites
Nootropic Agents
Lipotropic Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Antilipemic Agents
Gastrointestinal Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 17, 2008




Links to all studies - primarily for crawlers